###begin article-title 0
Comparison of Serum Beta 2-Microglobulin and 24 hour Urinary Creatinine Clearance as a Prognostic Factor in Multiple Myeloma
###end article-title 0
###begin p 1
###xml 111 112 108 109 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 184 185 178 179 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 276 277 267 268 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 535 536 523 524 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 678 679 666 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 696 697 681 682 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 710 711 695 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 767 768 749 750 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 781 782 763 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 809 810 791 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 327 335 <span type="species:ncbi:9606">patients</span>
###xml 395 403 <span type="species:ncbi:9606">patients</span>
###xml 857 865 <span type="species:ncbi:9606">patients</span>
###xml 941 949 <span type="species:ncbi:9606">patients</span>
A new staging system for multiple myeloma (MM) has utilized serum concentrations of beta 2-microglobulin (Sbeta2M) and albumin as important prognostic factors for survival. Since Sbeta2M is an indicator of glomerular filtration rate, we compared the prognostic values of Sbeta2M and 24-hr urinary creatinine clearance (Ccr) in patients with MM. We retrospectively reviewed the records of 170 MM patients from January 1996 to November 2003 whose 24-hr urinary Ccr was available at the time of diagnosis. We found that pretreatment Sbeta2M was inversely related to Ccr (Spearman's correlation coefficient=-0.787). In univariate analysis, the hazard ratio (HR) of death was 1.043 (p<0.001) for Sbeta2M and 0.985 (p<0.001) for Ccr. Multivariate analysis showed that Sbeta2M (HR 1.030, p=0.010) and Ccr (HR 0.993, p=0.059) were significant prognostic factors in patients' survival. In conclusion, 24-hr urinary Ccr may be utilized for staging of patients with MM.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 112 113 112 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Until recently, the Durie Salmon (DS) staging system was primarily used in patients with multiple myeloma (MM) (1). This staging system was designed according to cell mass, utilizing hemoglobin, serum calcium, lytic bone lesions, and M component production rates as measurements, with each stage divided into A and B subgroups according to renal function.
###end p 3
###begin p 4
###xml 115 116 112 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 154 155 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
More recently, the Southwest Oncology Group (SWOG) introduced a new staging system with beta 2-microglobulin (Sbeta2M) and albumin as prognostic factors (2). The SWOG staging system has been regarded as an easy, as well as good indicator of event-free survival, first-year mortality, and long-term survival. However, the SWOG system still requires more time and practice until it becomes the standard method.
###end p 4
###begin p 5
###xml 5 6 2 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 141 142 135 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 323 324 317 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 325 326 319 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
Sbeta2M, which is thought to reflect known tumor cell burden, has been regarded as the most important prognostic factor in MM. Although Sbeta2M concentration is influenced by kidney function, multivariate analysis showed that it remains an independent prognostic factor after correction for serum creatinine concentration (3-7).
###end p 5
###begin p 6
###xml 69 70 66 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 157 158 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 159 160 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 190 191 184 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 12 20 <span type="species:ncbi:9606">patients</span>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
###xml 345 353 <span type="species:ncbi:9606">patients</span>
However, in patients with mild to moderate renal insufficiency, Sbeta2M may be a better indicator of glomerular filtration rate (GFR) than serum creatinine (8,9). We therefore compared Sbeta2M with 24 urinary Ccr as prognostic factors in MM patients, and determined the significance of 24 hr urinary creatinine clearance (Ccr) in the staging of patients with MM.
###end p 6
###begin title 7
MATERIALS AND METHODS
###end title 7
###begin title 8
Subjects
###end title 8
###begin p 9
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
###xml 300 308 <span type="species:ncbi:9606">patients</span>
We retrospectively reviewed the records of all 268 symptomatic MM patients admitted and newly diagnosed at Asan Medical Center, Seoul, Korea, from 1 January 1996 to 30 November 2003. The 24-hr urinary Ccr was available at the time of diagnosis for 170 of these symptomatic MM patients, and these 170 patients were enrolled into the study. Survival time was followed until 30 April 2005.
###end p 9
###begin p 10
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 8 16 <span type="species:ncbi:9606">patients</span>
All the patients had symptomatic MM in accordance with the diagnostic criteria of the International Myeloma Working Group (2003) (11). These criteria are defined as: 1) M-protein in serum and/or urine; 2) bone marrow (clonal) plasma cells or plasmacytomas; 3) related organ or tissue impairment (end organ damage, including bone lesions); and 4) no minimal level of clonal bone marrow plasma cells.
###end p 10
###begin p 11
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with nonsecretory myeloma, smoldering multiple myeloma, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes), plasma cell leukemia, light chain deposit disease, MGUS (monoclonal gammopathy of undermined significance), extramedullary plasmacytoma, a combination of other malignancies, severe trauma were excluded.
###end p 11
###begin title 12
Parameters
###end title 12
###begin p 13
###xml 89 90 86 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 216 217 210 211 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 258 261 252 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
We investigated age, sex, heavy chain types, light chain types, Durie-Salmon stage, Sbeta2M, hemoglobin, serum calcium, serum albumin, serum creatinine, and 24 hr urine creatinine clearance before chemotherapy. Sbeta2M was measured by a radioimmunoassay with125I-labeled beta 2-microglobulin.
###end p 13
###begin title 14
Treatment
###end title 14
###begin p 15
###xml 164 165 164 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 8 16 <span type="species:ncbi:9606">patients</span>
Whereas patients received various treatments, they could be divided into 3 groups; those who received conservative treatment (no treatment or dexamethasone [20 mg/m2orally] only), those who received conventional chemotherapy (e.g., VAD, MP, high dose cytoxan plus predinisolone, and thalidomide plus dexamethasone regimens), and those who received autologous stem cell transplantation.
###end p 15
###begin p 16
###xml 45 46 45 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 73 74 73 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 158 159 158 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 290 291 290 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 328 329 328 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
The MP regimen consisted of melphalan (8 mg/m2) and prednisolone (60 mg/m2) for 4 days; the VAD regimen consisted of vincristine (0.4 mg), doxorubicin (9 mg/m2) for 4 days, and dexamethasone (40 mg) for 12 days. The high dose cytoxan plus prednisolone regimen consisted of cytoxan (400 mg/m2) for 1 day and prednisolone (40 mg/m2) for 7 days and was a variant of the VBMCP (vincristine, BCNU, melphalan, cytoxan, prednisolone) regimen. The thalidomide plus dexamethasone regimen consisted of 200 mg thalidomide orally per day plus 5 to 10 mg dexamethasone intravenously 4 times per day.
###end p 16
###begin title 17
Survival time
###end title 17
###begin p 18
###xml 59 67 <span type="species:ncbi:9606">patients</span>
###xml 214 221 <span type="species:ncbi:9606">patient</span>
Medical records were used to collect data. Interviews with patients' families by telephone and data from the hospital network connected to the Korean National Statistical Office were also utilized to determine the patient survival times.
###end p 18
###begin title 19
Staging system
###end title 19
###begin p 20
###xml 103 104 103 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 173 174 170 171 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 204 205 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients were divided depending on DS stage, which was assigned by physicians who first examined them (1). Then, they were resorted by SWOG staging system according to Sbeta2M and albumin concentrations (2).
###end p 20
###begin p 21
###xml 33 34 30 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 75 76 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 103 104 92 93 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 167 168 149 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
SWOG stage 1 was defined as Sbeta2M <2.5 mg/L; stage 2 as 2.5 mg/L </=Sbeta2M <5.5 mg/L; stage 3, Sbeta2M >/=5.5 mg/L and serum albumin >/=3.0 g/dL; and stage 4, Sbeta2M >/=5.5 mg/L and albumin <3.0 g/dL.
###end p 21
###begin p 22
During the course of this study, we formulated a new experimental staging system based on 24 hr urinary Ccr and serum albumin. In this system, stage 1 defined as Ccr >/=90 mL/min; stage 2 as 90 mL/min >Ccr >/=30 mL/min; stage 3 as Ccr <30 mL/min and albumin >/=3.0 g/dL; stage 4 as Ccr <30 mL/min and albumin <3.0 g/dL.
###end p 22
###begin title 23
Statistical analysis
###end title 23
###begin p 24
###xml 295 296 292 293 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 91 98 <span type="species:ncbi:9606">patient</span>
###xml 118 126 <span type="species:ncbi:9606">patients</span>
SPSS (version 11.0) was used to determine the means and standard deviations and medians of patient characteristics of patients and laboratory findings. One-way ANOVA and Student's t test were used to compare mean Ccr according to heavy or light chain types. An interactive graph of Ccr and Sbeta2M was drawn using a scatter plot and a logarithmic estimated curve.
###end p 24
###begin p 25
###xml 119 120 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
The Kaplan-Meier method was utilized for survival analysis with log rank test; statistical significance was defined as p value less than 0.05.
###end p 25
###begin p 26
The Cox proportional hazard model was employed for univariate analysis and multivariate analyses to confirm the significance of risk factors of death. In multivariate analysis, we used eliminated variables stepwise (backward) by a significance of less than 10%.
###end p 26
###begin title 27
RESULTS
###end title 27
###begin title 28
Study population
###end title 28
###begin p 29
###xml 678 685 678 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
###xml 158 166 <span type="species:ncbi:9606">patients</span>
###xml 183 191 <span type="species:ncbi:9606">patients</span>
###xml 233 241 <span type="species:ncbi:9606">patients</span>
###xml 506 514 <span type="species:ncbi:9606">patients</span>
From 1 January 1996, through 30 November 2003, 289 patients with plasma cell disorders were admitted to our Center. Among them, there were 268 symptomatic MM patients. We excluded 14 patients with other monoclonal gammopathies and 7 patients with combining other malignancy or severe trauma. Gammopathies other than symptomatic multiple myeloma were 3 MUGS, 2 plasma cell leukemia, 2 smoldering MM, 2 nonsecretory MM, 1 extramedullary plasmacytoma, 1 multiple solitary plasmacytoma, and 3 POEMS. As to 170 patients, 24-hr urinary creatinine clearance was available at the time of diagnosis. Baseline characteristics and laboratory findings at the time of diagnosis are shown in Table 1.
###end p 29
###begin p 30
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 293 294 293 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 336 337 333 334 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 414 415 411 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
###xml 163 171 <span type="species:ncbi:9606">patients</span>
###xml 228 236 <span type="species:ncbi:9606">patients</span>
###xml 342 350 <span type="species:ncbi:9606">patients</span>
Table 2 shows the mean Ccr of each type. The mean Ccr in patients with free light chain was lower than those of the heavy and light chain type groups. Mean Ccr of patients with free light chain was 36.2 mL/min, whereas those of patients with IgG type and IgA were 54.9 mL/min and 62.2 mL/min (p=0.005), respectively. However, mean Sbeta2M of patients according to heavy chain types was not significantly different(p=0.156).
###end p 30
###begin p 31
###xml 11 19 <span type="species:ncbi:9606">patients</span>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
###xml 271 279 <span type="species:ncbi:9606">patients</span>
###xml 407 415 <span type="species:ncbi:9606">patients</span>
Of the 170 patients, 28 patients were managed conservatively, 92 patients were treated with conventional chemotherapy, and 50 patients received high-dose chemotherapy with autologous stem cell transplantations. The first-line chemotherapy regimens consisted of VAD in 94 patients, MP in 41, cytoxan plus prednisolone in 4, thalidomide plus dexamethasone in 1. The chemotherapy regimen was unidentified in 2 patients.
###end p 31
###begin p 32
###xml 54 62 <span type="species:ncbi:9606">patients</span>
###xml 147 155 <span type="species:ncbi:9606">patients</span>
###xml 234 242 <span type="species:ncbi:9606">patients</span>
We could definitively identify cause of death only if patients died in hospital, although we attempted to interview by telephone family members of patients who died outside of hospital to exclude death by accidental trauma. Of the 51 patients who died in hospital, 28 died of sepsis, 9 of respiratory failure, 4 of heart failure, 2 of major bleeding, 1 of arrhythmia, 3 of acute renal failure, 1 of acute myocardial infarction, 1 of subdural hemorrhage, and 2 of hepatic failure.
###end p 32
###begin p 33
###xml 29 37 <span type="species:ncbi:9606">patients</span>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
###xml 230 237 <span type="species:ncbi:9606">persons</span>
Among the 268 symptomatic MM patients, only 3 patients had hemodialysis before diagnosis because of acute renal failure; these patients did not have any other specific etiology, such as diabetes mellitus or hypertension. In all 3 persons, Ccr was measured at diagnosis, and all 3 were enrolled in this study.
###end p 33
###begin title 34
Univariate and multivariate analysis
###end title 34
###begin p 35
###xml 75 76 72 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 220 227 217 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3</xref>
###xml 366 367 363 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 427 428 424 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 451 452 445 446 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 560 561 552 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 570 577 562 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">Table 4</xref>
###xml 518 526 <span type="species:ncbi:9606">patients</span>
Univariate analysis showed that age, serum calcium, serum creatinine, Sbeta2M, Ccr, free light chain type, and treatment modalities were significant prognostic factors, using both the continuous and dichotomous methods (Table 3). The conservative management group had a shorter life expectancy than both the conventional chemotherapy group (hazard ratio [HR] 2.021, p=0.004) and the autologous transplantation group (HR 9.020, p<0.001). However, Sbeta2M concentration was not significant in univariate analysis of 104 patients with Ccr >/=30 mL/min (HR 1.001, p=0.982) (Table 4).
###end p 35
###begin p 36
###xml 107 108 104 105 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 320 321 317 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 458 459 452 453 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 520 521 511 512 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 605 606 593 594 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Multivariate analysis of prognostic factors using the Cox proportional hazard model showed that serum Sbeta2M, creatinine clearance, and treatment modalities were significant prognostic factors in continuous method (Table 6). Ccr was of borderline significance and was not eliminated by backward stepwise calculation if p=0.10. Using the dichotomous method, however, the result was somewhat different. If the Ccr cut-off value was 30 mL/min and that of Sbeta2M was 5.5 mg/L, Ccr and treatment were significant, but Sbeta2M concentration was not. This discrepancy was due to the close relationship of Sbeta2M and Ccr, making it difficult to determine a standard cutoff value using the dichotomous method.
###end p 36
###begin title 37
Correlation of beta 2-microglobulin and creatinine clearance
###end title 37
###begin p 38
###xml 36 37 33 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 83 89 80 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 124 125 118 119 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 198 199 192 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
When we drew a scatter plot of Sbeta2M and Ccr prior to the start of chemotherapy (Fig. 1), we found that pretreatment Sbeta2M was inversely related to Ccr (Spearman's correlation efficient -0.787, p<0.001).
###end p 38
###begin title 39
Stage
###end title 39
###begin p 40
###xml 0 6 0 6 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 246 247 243 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 270 278 <span type="species:ncbi:9606">patients</span>
Fig. 2 shows survival curves relative to DS stage and SWOG stage. Because we enrolled only patients whose DS stage was recorded by doctors at the time of diagnosis, the total number according to DS stage was 147 (95 dead, 52 alive). Because Sbeta2M was not checked in 3 patients in the study group, the total number according to SWOG stage was 167 (112 dead, 55 alive).
###end p 40
###begin p 41
Median overall survival times according to DS stage were 919 days for stage 1 (n=11), 1011 days for stage 2 (n=17), 925 days for stage 3A (n=66), and 380 days for stage 3B (n=53).
###end p 41
###begin p 42
Median survival times according to SWOG stage were 1475 days for stage 1 (n=18), 917 days for stage 2 (n=65), 453 days for stage 3 (n=57), and 152 days for stage 4 (n=27) (log rank test <0.0001).
###end p 42
###begin title 43
Possible staging system
###end title 43
###begin p 44
###xml 101 102 98 99 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 208 209 202 203 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 232 238 226 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 51 58 <span type="species:ncbi:9606">patient</span>
Univariate analysis showed that, as Ccr increased, patient survival time increased. Furthermore Sbeta2M was closely related with Ccr. We therefore formulated a new staging system based on Ccr instead of Sbeta2M, plus serum albumin (Fig. 3). According to this system, stage 1 is Ccr >/=90 mL/min; stage 2 is 90 mL/min > Ccr >/=30 mL/min; stage 3 is Ccr <30 mL/ min and albumin >/=3.0 g/dL; stage 4, Ccr <30 mL/min and albumin <3.0 g/dL.
###end p 44
###begin p 45
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Applying this system, we found that 30 patients (12 dead, 18 alive) were stage 1, 74 (44 dead, 30 alive) were stage 2, 46 (42 dead, 4 alive) were stage 3, and 20 (17 dead, 3 alive) were stage 4.
###end p 45
###begin p 46
According to this staging system, the median survival times were 1,475 days for stage 1, 889 days for stage 2, 339 days for stage 3, and 95 days for stage 4 (log rank test <0.0001).
###end p 46
###begin title 47
DISCUSSION
###end title 47
###begin p 48
###xml 30 31 27 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 146 147 140 141 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 300 301 291 292 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
In MM, the importance of Sbeta2M has led to the introduction of the SWOG staging system. In an attempt to determine the relationship between Sbeta2M and kidney function and to choose a more significant prognostic factor, we were unable to find any study that included both 24 hr urinary Ccr and Sbeta2M as prognostic factors. Thus, to our knowledge, this study is the first to include both of these as prognostic factors.
###end p 48
###begin p 49
###xml 26 27 23 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 120 121 114 115 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 284 292 <span type="species:ncbi:9606">patients</span>
We found that in MM, Sbeta2M and Ccr were more closely related than we expected. Multivariate analysis showed that Sbeta2M, Ccr, and treatment modalities were independent prognostic factors. Thus, the results of this study suggest that Ccr is a new, powerful prognostic factor in the patients with MM. Moreover, this finding indicates that Ccr can be incorporated into a discrete new staging system for MM.
###end p 49
###begin p 50
###xml 29 30 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 144 145 138 139 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 266 267 257 258 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 272 279 <span type="species:ncbi:9606">patient</span>
It was interesting that Sbeta2M was not significant in patients whose Ccr was greater than 30 mL/min. That is, the incremental addition of Sbeta2M concentration was not a significant prognostic factor if kidney function was relatively good. Thus, the effect of Sbeta2M on patient survival might be mainly due to declining kidney function.
###end p 50
###begin p 51
###xml 48 49 45 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 205 206 199 200 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 271 272 262 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 373 374 364 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 375 377 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 572 573 560 561 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 142 149 <span type="species:ncbi:9606">patient</span>
###xml 748 756 <span type="species:ncbi:9606">patients</span>
###xml 1189 1197 <span type="species:ncbi:9606">patients</span>
Our new staging system used Ccr instead of Sbeta2M. The latter is not likely to be a specific tumor marker in MM. This finding indicates that patient survival is related to the decreased excretion of Sbeta2M rather than to its overproduction. There is evidence that Sbeta2M reflects glomerular filtration rate in many situations, although it also reflects tumor cell mass (9-11). Although our Kaplan-Meier curves of stages relative to Ccr and serum albumin concentrations were discrete, they were unable to show that Ccr was a more significant prognostic factor than Sbeta2M. These two factors, plus serum creatinine, are related, and other conflicting factors affect survival, thus making interpretation difficult. Differences in mean Ccr between patients with both heavy and light chains and those with only free light chains may be related to different survival times. Although the SWOG staging system has been regarded as easier and likely to supersede the DS staging system, it is cautious to determine the superiority between the two staging systems. Serum albumin was not a significant prognostic in univariate analysis, but, in the SWOG staging system, it was important in sorting patients with advanced stage MM.
###end p 51
###begin p 52
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
Our study had several limitations. First, we may have included patients who died accidentally, since the causes of death of patients who died outside the hospital could not be determined. Second, this retrospective study did not include important parameters such as performance status, C reactive protein, chromosome 13 abnormality, and plasma cell labeling index (12,13).
###end p 52
###begin p 53
###xml 55 56 52 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 184 185 178 179 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 257 258 248 249 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
In conclusion, we found that in patients with MM, Sbeta2M was an independent significant prognostic factor in multivariate analysis that included Ccr. Although closely related to Sbeta2M, Ccr was also a significant prognostic factor that could replace Sbeta2M in staging systems of MM. Mean Ccr differed among heavy chain types, and these differences were likely related to different survival times.
###end p 53
###begin article-title 54
A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
###end article-title 54
###begin article-title 55
###xml 42 50 <span type="species:ncbi:9606">patients</span>
A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience
###end article-title 55
###begin article-title 56
The prognostic value of serum beta 2-microglobulin compared with other presentation features in myelomatosis
###end article-title 56
###begin article-title 57
Beta 2-microglobulin in multiple myeloma
###end article-title 57
###begin article-title 58
Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma
###end article-title 58
###begin article-title 59
###xml 111 119 <span type="species:ncbi:9606">patients</span>
Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment; a prospective study of 160 patients
###end article-title 59
###begin article-title 60
Long-term prognostic value of serum beta 2 microglobulin in myelomatosis
###end article-title 60
###begin article-title 61
Cystatin C, beta 2-microglobulin, and retinol-binding protein as indicators of glomerular filtration rate: comparison with plasma creatinine
###end article-title 61
###begin article-title 62
Serum cystatin C and beta 2 microglobulin as markers of glomerular filtration rate
###end article-title 62
###begin article-title 63
Reappraisal of serum beta2-microglobulin as marker of GFR
###end article-title 63
###begin article-title 64
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
###end article-title 64
###begin article-title 65
###xml 132 140 <span type="species:ncbi:9606">patients</span>
Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy
###end article-title 65
###begin article-title 66
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma
###end article-title 66
###begin p 67
Relationship of beta 2-microglobulin and 24 hr urinary creatinine clearance before chemotherapy.
###end p 67
###begin p 68
Survival curves according to DS stage (A) and SWOG stage (B) with serum beta 2-microglobulin and serum albumin.
###end p 68
###begin p 69
Survival curves according to new staging system with Ccr and serum albumin.
###end p 69
###begin p 70
###xml 32 40 <span type="species:ncbi:9606">patients</span>
Baseline characteristics of the patients
###end p 70
###begin p 71
Types of heavy chains and light chains
###end p 71
###begin p 72
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 113 119 113 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
*p<0.05 between patients with IgG type and free light chain type, or between IgA type and free light chain type, daggerOne with only IgG heavy chain type was excluded.
###end p 72
###begin p 73
Hazard ratio in univariate analysis
###end p 73
###begin p 74
HR, hazard risk of death; NS, not significant.
###end p 74
###begin p 75
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
*heavy chain type, Free light chain type vs. both heavy and light chain type.
###end p 75
###begin p 76
Hazard ratio in univariate analysis if Ccr >/=30 mL/min
###end p 76
###begin p 77
###xml 5 6 2 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Sbeta2M, Serum beta 2-microglobulin; Ccr, Creatinine clearance; HR, hazard risk of death.
###end p 77
###begin p 78
Multivariate analysis by Cox proportional hazard model (backward)
###end p 78
###begin p 79
###xml 0 6 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
###xml 105 118 100 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8225;</sup>
daggerBorderline significant and not eliminated backward stepwise calculations at a significance of 10%; double daggerTreatments; 1) Conservative management, 2) Conventional chemotherapy, and 3) Autologous stem cell transplantation.
###end p 79
###begin p 80
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 66 67 61 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
*Dichotomous: Cutoff values were Ccr >/=30 or <30 mL/min and Sbeta2M >/=5.5 or <5.5 microg/mL.
###end p 80
###begin p 81
###xml 203 204 198 199 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 237 238 223 224 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 401 402 384 385 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Dichotomous results could not be accepted with confidence because the change in cutoff value of Ccr led to different outcomes. For example, if the cutoff value of Ccr was >/=50 or <50 mL/min and if Sbeta2M >/=5.5 or <5.5 microg/mL, Sbeta2M, treatment modalities, heavy chain type, serum calcium became significant prognostic factors. This result might be caused by the close relationship between Sbeta2M and Ccr.
###end p 81

